Keywords: lilly, evista, preliminary, breast, cancer, data, following
Lilly's Evista, Preliminary Breast Cancer Data
Article | 21 April 1998
Following the excitement generated by the release of data demonstratingthat tamoxifen reduces the risk of breast cancer by 45% (Marketletters passim), ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
